» Articles » PMID: 34205043

A New Chalcone Derivative with Promising Antiproliferative and Anti-Invasion Activities in Glioblastoma Cells

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2021 Jul 2
PMID 34205043
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma (GBM) is the most common and most deadly primary malignant brain tumor. Current therapies are not effective, the average survival of GBM patients after diagnosis being limited to few months. Therefore, the discovery of new treatments for this highly aggressive brain cancer is urgently needed. Chalcones are synthetic and naturally occurring compounds that have been widely investigated as anticancer agents. In this work, three chalcone derivatives were tested regarding their inhibitory activity and selectivity towards GBM cell lines (human and mouse) and a non-cancerous mouse brain cell line. The chalcone 1 showed the most potent and selective cytotoxic effects in the GBM cell lines, being further investigated regarding its ability to reduce critical hallmark features of GBM and to induce apoptosis and cell cycle arrest. This derivative showed to successfully reduce the invasion and proliferation capacity of tumor cells, both key targets for cancer treatment. Moreover, to overcome potential systemic side effects and its poor water solubility, this compound was encapsulated into liposomes. Therapeutic concentrations were incorporated retaining the potent in vitro growth inhibitory effect of the selected compound. In conclusion, our results demonstrated that this new formulation can be a promising starting point for the discovery of new and more effective drug treatments for GBM.

Citing Articles

Polymersomes for Sustained Delivery of a Chalcone Derivative Targeting Glioblastoma Cells.

Alves A, Silva A, Moreira J, Nunes C, Reis S, Pinto M Brain Sci. 2024; 14(1).

PMID: 38248297 PMC: 10813242. DOI: 10.3390/brainsci14010082.


Natural Chalcones and Derivatives in Colon Cancer: Pre-Clinical Challenges and the Promise of Chalcone-Based Nanoparticles.

Hba S, Ghaddar S, Wahnou H, Pinon A, El Kebbaj R, Pouget C Pharmaceutics. 2023; 15(12).

PMID: 38140059 PMC: 10748144. DOI: 10.3390/pharmaceutics15122718.


Microfluidic Devices: A Tool for Nanoparticle Synthesis and Performance Evaluation.

Gimondi S, Ferreira H, Reis R, Neves N ACS Nano. 2023; 17(15):14205-14228.

PMID: 37498731 PMC: 10416572. DOI: 10.1021/acsnano.3c01117.


Discovery of a New Chalcone-Trimethoxycinnamide Hybrid with Antimitotic Effect: Design, Synthesis, and Structure-Activity Relationship Studies.

Moreira J, Silva P, Barros M, Saraiva L, Pinto M, Bousbaa H Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375826 PMC: 10303900. DOI: 10.3390/ph16060879.


Anticancer Activity of Chalcones and Its Derivatives: Review and In Silico Studies.

Leite F, de Sousa N, Oliveira B, Duarte G, Leite Ferreira M, Scotti M Molecules. 2023; 28(10).

PMID: 37241750 PMC: 10223217. DOI: 10.3390/molecules28104009.


References
1.
Qazi M, Vora P, Venugopal C, Sidhu S, Moffat J, Swanton C . Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol. 2017; 28(7):1448-1456. DOI: 10.1093/annonc/mdx169. View

2.
Lima A, Campos C, Cunha C, Carvalho A, Reis R, Ferreira H . Biofunctionalized Liposomes to Monitor Rheumatoid Arthritis Regression Stimulated by Interleukin-23 Neutralization. Adv Healthc Mater. 2020; 10(2):e2001570. DOI: 10.1002/adhm.202001570. View

3.
Lahsasni S, Al Korbi F, Aljaber N . Synthesis, characterization and evaluation of antioxidant activities of some novel chalcones analogues. Chem Cent J. 2014; 8:32. PMC: 4026827. DOI: 10.1186/1752-153X-8-32. View

4.
Xu S, Chen M, Chen W, Hui J, Ji J, Hu S . Chemopreventive effect of chalcone derivative, L2H17, in colon cancer development. BMC Cancer. 2015; 15:870. PMC: 4638100. DOI: 10.1186/s12885-015-1901-x. View

5.
Pinto P, Machado C, Moreira J, Almeida J, Silva P, Henriques A . Chalcone derivatives targeting mitosis: synthesis, evaluation of antitumor activity and lipophilicity. Eur J Med Chem. 2019; 184:111752. DOI: 10.1016/j.ejmech.2019.111752. View